Safety and Efficacy of Prophylactic Defibrotide in Children, Adolescents, and Young Adults With Sickle Cell Disease Following MAC and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback

Trial Profile

Safety and Efficacy of Prophylactic Defibrotide in Children, Adolescents, and Young Adults With Sickle Cell Disease Following MAC and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs Defibrotide (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Dec 2017 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
    • 14 Dec 2017 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.
    • 05 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top